It’s been a long seven months for Perrigo's HRA Pharma, the company making a historic request to expand American access to birth control. But at least, after nine years of regulatory red tape, its executives know how to be patient.
In July, the pharmaceutical company made a landmark—and tragically well-timed—application to the U.S. Food and Drug Administration. The Supreme Court had just overturned Roe v. Wade. And as tens of millions of women lost access to abortion almost overnight, the Court also signaled that access to contraceptives could be next in the legal crosshairs.
.jpg?w=600)
